Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study.
chronic lymphocytic leukemia
death
disability-adjusted life years
epidemiology
incidence
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
07
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
The prognosis of chronic lymphocytic leukemia (CLL) has been improved dramatically, but there are limited studies focusing on CLL disease burden on a global scale. We aimed to evaluate the accurate assessment of the disease burden of CLL that may provide more detailed epidemiological information for rational policies. The main source of the data was the Global Burden of Disease (GBD) study 2019. Incident cases, death cases, disability-adjusted life years (DALYs), and their corresponding age-standardized rates (ASRs) from 1990 to 2019 were used to describe the burden of CLL. Data about attributable risk factors were also extracted and analyzed. Bayesian age-period-cohort (BAPC) models were used to assess and project the incidence and mortality rates till 2030. Globally, the incidence of CLL had been increasing. Deaths and DALYs decreased slightly. The burden of death and DALY is affected by socio-demographic index (SDI). The incidence rate, death rate, and DALY rate of CLL increased significantly with age. Male-to-female ratios of incidence rates varied in different SDI quintiles. Smoking, high body mass index, and occupational exposure to benzene or formaldehyde were the potential risk factors related to CLL. Global ASIRs might tend to increase until 2030, while ASDR would decrease until 2030. The disease burden of CLL decreased in higher SDI countries but increased in lower ones. Strategies for early detection of asymptomatic CLL, development of novel drugs, and measures against attributable factors should be implemented to combat CLL burden.
Sections du résumé
Background
UNASSIGNED
The prognosis of chronic lymphocytic leukemia (CLL) has been improved dramatically, but there are limited studies focusing on CLL disease burden on a global scale. We aimed to evaluate the accurate assessment of the disease burden of CLL that may provide more detailed epidemiological information for rational policies.
Methods
UNASSIGNED
The main source of the data was the Global Burden of Disease (GBD) study 2019. Incident cases, death cases, disability-adjusted life years (DALYs), and their corresponding age-standardized rates (ASRs) from 1990 to 2019 were used to describe the burden of CLL. Data about attributable risk factors were also extracted and analyzed. Bayesian age-period-cohort (BAPC) models were used to assess and project the incidence and mortality rates till 2030.
Results
UNASSIGNED
Globally, the incidence of CLL had been increasing. Deaths and DALYs decreased slightly. The burden of death and DALY is affected by socio-demographic index (SDI). The incidence rate, death rate, and DALY rate of CLL increased significantly with age. Male-to-female ratios of incidence rates varied in different SDI quintiles. Smoking, high body mass index, and occupational exposure to benzene or formaldehyde were the potential risk factors related to CLL. Global ASIRs might tend to increase until 2030, while ASDR would decrease until 2030.
Conclusion
UNASSIGNED
The disease burden of CLL decreased in higher SDI countries but increased in lower ones. Strategies for early detection of asymptomatic CLL, development of novel drugs, and measures against attributable factors should be implemented to combat CLL burden.
Identifiants
pubmed: 35359356
doi: 10.3389/fonc.2022.840616
pmc: PMC8961301
doi:
Types de publication
Journal Article
Langues
eng
Pagination
840616Informations de copyright
Copyright © 2022 Ou, Long, Ji, Zhan, Qiao, Wang, Chen and Cheng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Asian Pac J Cancer Prev. 2015;16(2):793-6
pubmed: 25684527
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Blood. 2021 Sep 9;138(10):836-846
pubmed: 34115103
Cancer Res Treat. 2020 Apr;52(2):351-358
pubmed: 32178488
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Genet. 2013 Aug;45(8):868-76
pubmed: 23770605
Rev Clin Esp. 1963 Oct 15;91:17-22
pubmed: 14113319
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):3-5
pubmed: 26667885
Cancer. 1995 Jan 1;75(1 Suppl):381-94
pubmed: 8001009
J Hepatol. 2019 Apr;70(4):674-683
pubmed: 30543829
Br Med J. 1955 Nov 12;2(4949):1172-6
pubmed: 13269823
Blood. 2018 May 24;131(21):2357-2366
pubmed: 29483101
Clin Epidemiol. 2018 Mar 09;10:277-288
pubmed: 29563840
Aging (Albany NY). 2020 Feb 8;12(3):2545-2583
pubmed: 32035421
Front Public Health. 2020 Dec 11;8:598215
pubmed: 33363091
Biomark Res. 2020 May 13;8:16
pubmed: 32435498
Biom J. 2017 May;59(3):531-549
pubmed: 28139001
Cancer Epidemiol. 2019 Jun;60:8-15
pubmed: 30878799
Am J Epidemiol. 1982 May;115(5):720-8
pubmed: 7081203
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
Blood. 2011 Feb 10;117(6):1911-6
pubmed: 21131588
Leuk Lymphoma. 2012 Oct;53(10):1961-5
pubmed: 22475243
Int J Clin Pract. 2021 Aug;75(8):e14258
pubmed: 33884738
Br J Haematol. 1961 Jan;7:73-98
pubmed: 13703205
Am J Hematol. 2016 Mar;91(3):330-40
pubmed: 26690614
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Front Oncol. 2019 Feb 21;9:98
pubmed: 30847304
Br J Haematol. 2012 Dec;159(5):572-6
pubmed: 23025533
Blood Rev. 2015 May;29(3):205-13
pubmed: 25541495
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):10-17
pubmed: 33275712
Eur J Haematol. 2010 Dec;85(6):492-5
pubmed: 20731705
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
Afr Health Sci. 2010 Jun;10(2):187-92
pubmed: 21326974
Front Oncol. 2020 Dec 15;10:580759
pubmed: 33384954
Cancer Commun (Lond). 2020 Nov;40(11):598-610
pubmed: 32936522
Nat Rev Cancer. 2006 Jan;6(1):63-74
pubmed: 16372017
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
BMC Med Res Methodol. 2020 Oct 15;20(1):257
pubmed: 33059585
Curr Treat Options Oncol. 2020 Mar 13;21(4):24
pubmed: 32170458
Leukemia. 2021 Feb;35(2):433-439
pubmed: 33077870
JCO Glob Oncol. 2021 Jan;7:56-62
pubmed: 33434067
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
BMC Res Notes. 2019 Apr 2;12(1):202
pubmed: 30940190
BMC Urol. 2019 Jul 5;19(1):59
pubmed: 31277621
Gastroenterology. 2018 May;154(6):1719-1728.e5
pubmed: 29549041
Lancet Haematol. 2018 Jan;5(1):e14-e24
pubmed: 29304322
Cancer Epidemiol. 2018 Feb;52:106-111
pubmed: 29289901
Cancer Causes Control. 2008 May;19(4):379-90
pubmed: 18064533
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
Int J Environ Res Public Health. 2021 Jan 15;18(2):
pubmed: 33467494
Blood. 2012 Jul 26;120(4):843-6
pubmed: 22700719
JCO Glob Oncol. 2020 Jul;6:1124-1133
pubmed: 32692628
Int J Cancer. 2017 Sep 15;141(6):1140-1147
pubmed: 28571111
Br J Cancer. 2011 Nov 22;105(11):1684-92
pubmed: 22045184
Aging (Albany NY). 2021 Apr 4;13(7):10468-10489
pubmed: 33820874